B-type Natriuretic Peptides in the Management of Acute Heart Failure and Acute Coronary Syndromes

2007 ◽  
Vol 3 (2) ◽  
pp. 22
Author(s):  
Torbjørn Omland ◽  
Keyword(s):  
Heart Failure ◽  
Acute Heart Failure ◽  
Natriuretic Peptides ◽  
Acute Coronary Syndromes ◽  
Coronary Syndromes

scholarly journals Natriuretic peptides and multimarker approach to risk stratification of patients with acute coronary syndromes

2006 ◽  
Vol 59 (5-6) ◽  
pp. 248-252 ◽  
Author(s):  
Radomir Matunovic ◽  
Aleksandar Stojanovic ◽  
Zdravko Mijailovic ◽  
Zoran Cosic
Keyword(s):  
Heart Failure ◽  
Risk Stratification ◽  
Natriuretic Peptides ◽  
Acute Coronary Syndromes ◽  
Cardiac Biomarkers ◽  
Therapeutic Implications ◽  
Coronary Syndrome ◽  
Brain Natriuretic Peptides ◽  
Coronary Syndromes ◽  
St Elevation

Natriuretic peptides in acute coronary syndromes Brain natriuretic peptides (BNP) and N-terminal prohormone brain natriuretic peptides (N-proBNP) have been shown to provide important prognostic information in patients with acute coronary syndrome (ACS). Ischemia may be an important stimulus for BNP release. This does not imply, however, that BNP is useful for diagnosing ischemia, and BNP is unlikely to prove sensitive or specific enough for this purpose. Significance of natriuretic peptides in assessing prognosis in patients with acute coronary syndromes In patients with ST-elevation and non-ST-elevation myocardial infarction, higher BNP and N-proBNP levels have been shown to predict a grater likelihood of death or heart faiulure, independent of other prognostic factors. Therapeutic implications of BNP elevation in acute coronary syndromes Patients with BNP or NT-proBNP elevation following ACS are clearly at high risk for death and for developement of heart failure, but specific therapeutic implications of BNP elevation have not been defined. In particular, it is not known how patients with BNP elevation should be treated considering the fact that they have normal troponin levels and no clinical evidence of heart failure. Multimarker strategies for risk stratification in acute coronary syndromes It has been shown recently that in patients with acute coronary syndromes the risk increased sequentially among those with one, two or three elevated biomarkers. Therapeutic applications of cardiac biomarkers in acute coronary syndromes Multimarker strategies, that incorporate panels of cardiac bio?markers, are likely to be used in the future for risk stratification and for pathophysiologically-guided treatement of patients with ACS.

scholarly journals Acute Heart Failure Complicating Acute Coronary Syndromes

Circulation ◽  
2004 ◽  
Vol 109 (4) ◽  
pp. 440-442 ◽  
Author(s):  
Eric J. Velazquez ◽  
Marc A. Pfeffer
Keyword(s):  
Heart Failure ◽  
Acute Heart Failure ◽  
Acute Coronary Syndromes ◽  
Coronary Syndromes

Acute Heart Failure in the Setting of Acute Coronary Syndromes

2008 ◽  
pp. 168-182
Author(s):  
José López-Sendón ◽  
Esteban López de Sá
Keyword(s):  
Heart Failure ◽  
Acute Heart Failure ◽  
Acute Coronary Syndromes ◽  
Coronary Syndromes

Circulating B-type natriuretic peptides in patients with acute coronary syndromes

2005 ◽  
Vol 94 (11) ◽  
pp. 926-932 ◽  
Author(s):  
Rudolf Jarai ◽  
Johann Wojta ◽  
Kurt Huber
Keyword(s):  
Heart Failure ◽  
Natriuretic Peptides ◽  
Acute Coronary Syndromes ◽  
Underlying Disease ◽  
High Risk Group ◽  
Coronary Syndromes ◽  
Short And Long Term ◽  
Underlying Mechanisms ◽  
Relationship Of

SummaryFifty percent of patients who experience death or develop heart failure after acute coronary syndromes (ACS) have extremely elevated concentrations of plasma B-type natriuretic peptides. These elevations, however, seem not to reflect permanent ventricular dysfunction or heart failure and are assumed to exist already at the onset of ischemic symptoms. The underlying mechanisms of BNP/Nt-proBNP elevations in patients withACS are still not known at present. Furthermore, the relationship of elevated BNP/Nt-proBNP with mortality but not with atherothrombotic complications of underlying disease makes it difficult to choose optimal therapeutic strategies based on plasma levels of these peptides. The remarkably high short- and long-term mortality rate associated with increases of BNP/Nt-proBNP elevations clearly show the need of further investigation to focus on this high-risk group of patients in order to clarify underlying pathomechanisms and to find optimal therapeutic approaches.

Tezosentan in patients with acute heart failure and acute coronary syndromes: Design of the Randomized Intravenous Tezosentan Study (RITZ-4)

2002 ◽  
Vol 144 (4) ◽  
pp. 583-588
Author(s):  
Christopher M. O'Connor ◽  
Wendy A. Gattis ◽  
Kirkwood F. Adams ◽  
Monica R. Shah ◽  
Isaac Kobrin ◽  
...  
Keyword(s):  
Heart Failure ◽  
Acute Heart Failure ◽  
Acute Coronary Syndromes ◽  
Coronary Syndromes

Acute Heart Failure With and Without Concomitant Acute Coronary Syndromes: Patient Characteristics, Management, and Survival

2014 ◽  
Vol 20 (10) ◽  
pp. 723-730 ◽  
Author(s):  
Tuukka Tarvasmäki ◽  
Veli-Pekka Harjola ◽  
Markku S. Nieminen ◽  
Krista Siirilä-Waris ◽  
Jukka Tolonen ◽  
...  
Keyword(s):  
Heart Failure ◽  
Acute Heart Failure ◽  
Acute Coronary Syndromes ◽  
Patient Characteristics ◽  
Coronary Syndromes
Sign in / Sign up

Export Citation Format

Share Document